Compare GSK plc (GSK) vs Nu Holdings Ltd (NU) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

NU Holdings Ltd. (NU) trades at $13.99, up 2.34% on the day, with a bullish technical outlook and strong fundamental growth. The stock shows robust revenue expansion from $10.63B in 2025 to projected $11.9B in 2026, with net income margins exceeding 26%. Recent news highlights Mexico banking approval and leadership changes, signaling international expansion momentum. Analyst consensus is bullish with a $14.98 price target, though recent earnings have missed expectations.

The outlook for NU remains positive due to its digital banking disruption in Latin America, high profitability, and undervaluation relative to growth. Key risks include currency volatility, credit exposure in emerging markets, and competitive pressures. Institutional sentiment is supportive, but investors should monitor execution on international expansion and earnings consistency for sustained upside.